Alzheimer's disease is one of the most severe neurodegenerative conditions. As the disease progresses, memory and cognitive functions decline, and behavioral changes and restlessness may also occur. In the brain, the accumulation of amyloid-beta proteins and abnormalities in the tau protein play an important role, among other factors.

Despite the vast amount of research, there is still no treatment that can cure Alzheimer's. That is precisely why it is interesting that in recent years, scientists have increasingly focused on a system that is already naturally present in our bodies: the endocannabinoid system (ECS).

In his recent article 'Cannabis Opens New Doors in Alzheimer's', Peter Vermeul explores what the current scientific literature tells us about this. In doing so, he looks not only at CBD or THC as individual substances, but at the broader range of cannabinoids, cannabinoid acids, terpenes, flavonoids, and sterols that occur together in a Full Spectrum cannabis extract.

And it is precisely this broader perspective that makes the research particularly interesting.

The endocannabinoid system: the connecting link

The endocannabinoid system can be seen as a finely tuned regulatory network in the body. It consists, among other things, of endogenous cannabinoids such as anandamide and 2-AG, cannabinoid receptors such as CB1 and CB2, and enzymes that produce and break down these endogenous substances.

This system is involved in a variety of processes that are important for the brain, including communication between nerve cells, immune responses, memory, mood, pain perception, and inflammatory processes.

In Alzheimer's, this system appears to change. Research shows, for example, that CB2 receptors increase in certain immune cells around amyloid plaques. Furthermore, animal research shows that CB2 stimulation is associated with reduced microglial cell activity and improved clearance of amyloid-beta.

This raises an interesting question: can substances from the cannabis plant support or influence this natural regulatory system?

This is where an important part of current research begins.

Why CBD does not tell the whole story

CBD is now a well-known cannabinoid. It is not psychoactive and does not act directly as a classic agonist on CB1 or CB2 receptors. However, CBD can indirectly influence the endocannabinoid system and, according to preclinical research, possesses anti-inflammatory and antioxidant properties.

Interesting effects have been observed in several animal models of Alzheimer's. For example, research was conducted on the influence of CBD on the loss of neural connections, amyloid-beta, inflammatory processes, and cognitive functions. In certain models, an improvement in learning ability and memory was observed.

But there is another aspect that is particularly relevant to Peter Vermeul: the acidic forms of cannabinoids.

In an unprocessed cannabis plant, cannabinoids occur largely as their acidic precursors, including CBDa and THCa. These substances are not the same as CBD and THC.

According to the studies discussed in the article, CBDa and THCa can cross the blood-brain barrier in animal models. In addition, effects were observed on both amyloid-beta and tau pathology, as well as cognitive decline, in Alzheimer's-like mouse models.

This makes CBDa an interesting area of research that is still very much under development.

The power of the whole plant

Anyone who looks only at CBD is actually looking at just one part of a much more complex plant.

In addition to cannabinoids, cannabis also contains terpenes, flavonoids, and phytosterols. Each of these substances has its own biological properties. In a Full Spectrum extract, several of these plant compounds remain present together.

This aligns with the so-called entourage effect: the idea that different components of the plant can influence and possibly enhance each other when they are present together.

This is not evidence that every Full Spectrum extract automatically works therapeutically. However, it does mean that scientists are becoming increasingly interested in the plant as a whole rather than exclusively in one isolated molecule.

And when we look at Alzheimer's, that perspective may be particularly interesting.

Terpenes and flavonoids: small substances with a large area of research

One example is β-caryophyllene, a terpene that also occurs in black pepper, among others. Laboratory research investigated whether this substance can protect nerve cells from damage caused by amyloid-beta.

α-pinene and β-pinene have also been studied. In cell models, these terpenes showed neuroprotective properties, and an inhibition of the formation of certain amyloid structures was observed.

In addition, there are cannabis-specific flavonoids, including cannflavins. In laboratory research, cannflavin A showed a protective effect against amyloid-beta-related cell damage and influenced the aggregation of amyloid-beta.

At the same time, it is important to continue to distinguish between what is observed in a laboratory or animal model and what has actually been proven in humans. Peter Vermeul therefore emphasizes that specific research on cannabis flavonoids in Alzheimer's is still limited.

That is precisely why further research is so important.

Phytosterols also appear to be interesting

Another example is β-sitosterol, a plant sterol that also occurs in cannabis.

In an Alzheimer's mouse model, long-term administration of β-sitosterol was associated with improved spatial memory, reduced amyloid plaque formation, and partial restoration of synaptic structures in the hippocampus.

This creates an increasingly interesting picture. Perhaps the value of a Full Spectrum extract lies not in one individual substance, but precisely in the presence of multiple plant components that can each act on different biological processes.

This aligns with what Peter Vermeul calls the multi-target effect of cannabis in his article.

From the laboratory to humans: what do we already know?

Preclinical research is promising, but ultimately the most important question is, of course: do we see this in humans too?

The answer at this moment is cautiously positive, but certainly not yet definitive.

In the article, Peter Vermeul discusses several clinical studies. For example, he describes a randomized phase II study in which people with Alzheimer's received a low-dose THC-CBD extract or a placebo for 26 weeks. At the end of the treatment, a significant improvement in the MMSE memory score was found in the cannabis group. The study was relatively small and the improvement was limited, but the result is interesting because it shows that low doses can also be investigated.

Other studies have mainly looked at behavioral problems and agitation in people with dementia. In the studies discussed by Vermeul, reductions in agitation and certain behavioral symptoms were observed with cannabis or CBD treatments, among other things.

But the same applies here: the studies are still relatively small, differ in the products and dosages used, and often have a limited research duration.

Furthermore, there has been hardly any clinical research conducted on specifically formulated Full Spectrum extracts with a fixed composition in people with early Alzheimer's.

That is an important distinction.

CBDa and Alzheimer's: promising research, no proven treatment

The results from laboratory and animal research are interesting enough to warrant further investigation. In several Alzheimer's mouse models, effects of CBDa and THCa on amyloid-beta, phosphorylated tau, and memory functions have been described.

But a mouse model is not a human.

That is why we at CBD & Herb want to handle this information carefully. Full Spectrum CBDa oil cannot be presented as a proven treatment or cure for Alzheimer's based on current research. Larger and longer-term clinical studies are needed for that.

What the research does do is open a door to a different perspective: perhaps cannabinoids and other substances from the cannabis plant can influence different processes involved in neurodegeneration.

And that is precisely why this area of research is so interesting.

Why Full Spectrum is such an important part of the research

Peter Vermeul draws a clear conclusion in his article: we should not reduce cannabis to a single molecule.

After all, in complex conditions such as Alzheimer's, multiple processes play a role at the same time. Inflammation, oxidative stress, changes in nerve communication, and protein accumulations cannot be viewed in isolation.

A complete cannabis extract contains several types of compounds that may each act on different processes: cannabinoids, cannabinoid acids, terpenes, flavonoids, and sterols.

That is also the reason why, within research on Full Spectrum extracts, there is an increasing focus on the whole plant and the interaction between plant substances, rather than exclusively on CBD as an isolated substance.

An important caveat: more is not always better

When using cannabinoids, dosage is an important topic. The article describes, among other things, that CBD can exhibit a so-called hormetic pattern in some research models: a low dose may have a different effect than a much higher dose. A higher amount does not therefore automatically mean a stronger or better effect.

Safety also deserves extra attention in older adults. Cannabinoids can interact with medications because they can influence liver enzymes such as cytochrome P450. In addition, the psychoactive effects of THC may be relevant in older adults due to confusion, dizziness, or fall risk, for example.

Anyone who wants to use cannabinoids alongside existing medication should therefore wisely discuss this carefully with a doctor or other expert who can assess the medication and possible interactions.

A research area that is just beginning to open

Perhaps that is ultimately the most important message from Peter Vermeul's article.

We are not at the end of a proven treatment course, but at the beginning of an interesting area of research.

The initial results indicate that cannabinoids and other substances from cannabis can influence different processes involved in Alzheimer's. At the same time, the scientific evidence in humans is still insufficient to draw firm therapeutic conclusions from this.

That does not make the topic any less interesting. On the contrary.

Precisely because the cannabis plant contains so many different bioactive substances, it creates a field of research in which there is still much to discover. The combination of CBDa, CBD, other cannabinoids, terpenes, flavonoids, and sterols could, according to current research literature, work on multiple points of action at the same time.

When future research confirms these initial results, Full Spectrum cannabis extracts could potentially take on a complementary role in supporting people with neurodegenerative conditions. But more well-designed clinical research is necessary for that.

Want to know more about Peter Vermeul's research?

This article is merely an accessible introduction to a much more extensive scientific story. In his full article, Peter Vermeul discusses the action of the endocannabinoid system, the role of CBDa and THCa, the influence of terpenes and flavonoids, results from Alzheimer's mouse models, and the initial clinical studies in humans.

Want to dive deeper into the subject? Then read Peter Vermeul's full article: 'Cannabis Opens New Doors in Alzheimer's'.

• Cannabis Opens New Doors in Alzheimer's - pdf NL
• Cannabis Opens New Doors in Alzheimer's - pdf EN 

At CBD & Herb, we follow these developments closely. Through our collaboration with CBD Spain, we share new insights from scientific research and help people to better inform themselves about Full Spectrum CBDa oil and the role cannabinoids may have within a broader, natural approach to health.

Important: the information in this article is based on Peter Vermeul's article and the scientific literature discussed therein. Research into cannabis, CBDa, and Alzheimer's is still very much under development. Full Spectrum CBDa oil is not a proven medicine for Alzheimer's and does not replace regular medical treatment or prescribed medication.